Clinical Trials Logo

Carcinoma, Renal Cell clinical trials

View clinical trials related to Carcinoma, Renal Cell.

Filter by:

NCT ID: NCT00915993 Recruiting - Kidney Cancer Clinical Trials

MRI in Predicting Response to Sunitinib Malate in Patients With Stage IV Kidney Cancer

Start date: May 2009
Phase: N/A
Study type: Interventional

RATIONALE: Diagnostic procedures, such as MRI, may help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This clinical trial is studying MRI in predicting response to sunitinib malate in patients with stage IV kidney cancer.

NCT ID: NCT00913913 Terminated - Clinical trials for Metastatic Renal Cell Carcinoma

Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients

Start date: February 2009
Phase: Phase 2
Study type: Interventional

Immune therapies, such as a IL-2, for metastatic renal cell carcinoma (mRCC) are designed to mobilize immune effector cells that recognize and destroy cancer. The investigators have recently observed a 50% objective response rate (16% CR) in mRCC patients treated with autologous tumor lysate -dendritic cell (DC)-vaccine, IL-2 and interferon alfa (IFN). New agents inhibiting vascular endothelial growth factor (VEGF) pathways have demonstrated significant benefit in mRCC patients as well, but rarely induce CRs. High blood VEGF is associated with poor response to IL-2 and can cause tumor specific immune dysregulation. To test whether complementary mechanisms of immune activation and disruption of regulatory pathways enhance outcome the investigators plan to treat 24 mRCC patients in a phase II trial using bevacizumab, DC vaccine, IL-2, and IFN. Observations from this project will be used in the development of novel cancer therapies which, if successful, will decrease the burden of cancer on the public. The investigators propose to determine 1) the objective clinical response rate to treatment and progression free survival, 2) the clinical and autoimmune related toxicity profile of therapy, and 3) the treatment related tumor-specific immune response and the relationship of tumor-specific immune response and objective clinical response.

NCT ID: NCT00908739 Withdrawn - Kidney Cancer Clinical Trials

Studying Tumor Tissue Samples From Patients Who Have Undergone Surgery for Localized Kidney Cancer

Start date: May 2008
Phase: N/A
Study type: Observational

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is looking at tumor tissue samples from patients who have undergone surgery for localized kidney cancer.

NCT ID: NCT00903175 Completed - Clinical trials for Renal Cell Carcinoma

Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma

RECORD-3
Start date: October 2009
Phase: Phase 2
Study type: Interventional

This study will assess the efficacy and safety of first-line RAD001 followed by second-line sunitinib versus the opposite sequence: first-line sunitinib followed by second-line RAD001 for the treatment of patients with MRCC.

NCT ID: NCT00900536 Completed - Kidney Cancer Clinical Trials

DNA Analysis of Blood and/or Tissue Samples From Patients With Primary Kidney Cancer Receiving Sorafenib on Clinical Trial MRC-RE05-SORCE

Start date: July 2007
Phase: N/A
Study type: Observational

RATIONALE: Studying samples of blood and/or tissue in the laboratory from patients with kidney cancer receiving sorafenib may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how well patients will respond to sorafenib. PURPOSE: This research study is looking at the DNA in blood and/or tissue samples from patients with primary kidney cancer receiving sorafenib on clinical trial MRC-RE05-SORCE.

NCT ID: NCT00900276 Completed - Bladder Cancer Clinical Trials

Biomarkers in Patients With Kidney Cancer or Cancer of the Urothelium and in Healthy Participants

Start date: June 2006
Phase:
Study type: Observational

RATIONALE: Studying samples of blood and urine from patients with cancer and from healthy participants in the laboratory may help doctors identify and learn more about biomarkers related to cancer. PURPOSE: This laboratory study is looking at biomarkers in patients with kidney cancer or cancer of the urothelium and in healthy participants.

NCT ID: NCT00900042 Completed - Kidney Cancer Clinical Trials

SWOG-9023, DNA Analysis of Tumor Tissue From Patients With Metastatic Kidney Cancer

Start date: July 1993
Phase: N/A
Study type: Observational

RATIONALE: DNA analysis of tumor tissue may help doctors predict how well patients will respond to treatment. PURPOSE: This laboratory study is analyzing the DNA in tumor tissue from patients with metastatic kidney cancer.

NCT ID: NCT00899860 Terminated - Kidney Cancer Clinical Trials

Gene Expression in Normal Tissue and Tumor Tissue From Patients Who Have Undergone Surgery For Kidney Cancer

Start date: September 2003
Phase: N/A
Study type: Observational

RATIONALE: Studying the genes and proteins expressed in tissue samples from patients with cancer may help doctors identify biomarkers related to cancer. PURPOSE: This laboratory study is evaluating gene and protein expression in normal tissue and tumor tissue from patients who have undergone surgery for kidney cancer.

NCT ID: NCT00898365 Recruiting - Clinical trials for Renal Cell Carcinoma

Study of Kidney Tumors in Younger Patients

Start date: February 27, 2006
Phase:
Study type: Observational

This research trial studies kidney tumors in younger patients. Collecting and storing samples of tumor tissue, blood, and urine from patients with cancer to study in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer.

NCT ID: NCT00896454 Completed - Breast Cancer Clinical Trials

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Start date: November 16, 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the potential of denosumab to treat Hypercalcemia of Malignancy in patients with elevated serum calcium who do not respond to recent treatment with intravenous bisphosphonates by lowering corrected serum calcium </= 11.5 mg/dL (2.9 millimoles /L) by day 10.